Randomized Controlled Trial of Higher-Volume Feedings in Preterm Neonates

June 14, 2018 updated by: Colm Travers, University of Alabama at Birmingham
The primary hypothesis is that preterm infants who are less than or equal to 32 weeks gestation and weigh 1001-2500 grams at birth will have an increase in weight gain with a feeding goal of 180-200 ml/kg/day more than the commonly used feeding goal of 140-160 ml/kg/day

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The proposed trial is designed to test the primary hypothesis that in preterm infants weighing 1001-2500 grams at birth and who are less than or equal to 32 weeks gestation, feeding goals of 180-200 ml/kg/day will increase weight gain (g/k/day) from time of enrollment to discharge home or 36 weeks post-menstrual age (PMA)(whichever comes first) more than the commonly used feeding goal volume of 140-160 ml/kg/day (usual feeding goal). This is a pilot study to determine the safety of increased volumes of feedings as opposed to fortification of feedings.

Study Type

Interventional

Enrollment (Actual)

224

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35249
        • University of Alabama at Birmingham

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 1 month (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inborn or outborn infants born at a gestational age of 32 weeks or less; Birthweight 1001-2500; Feeding volume of at least 120 ml/kg/day; Enrolled prior to 28 days of age and prior to exceeding 32 weeks

Exclusion Criteria:

  • Hemodynamically significant patent ductus arteriosis; History of necrotizing enterocolitis Bell Stage II or greater; Known gastrointestinal or neurologic malformations; Prior or planned enrollment into the NICHD MILK Trial; Terminal illness or decision to withhold or limit support

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Higher Volume Feeding Goal
Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
feeding volume goal of 180-200 ml/kg/day
No Intervention: Usual Volume Feeding Goal
Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight gain
Time Frame: baseline to average 12 weeks of age
Average change in weight between baseline and 12 weeks
baseline to average 12 weeks of age

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mid arm circumference
Time Frame: baseline to average 12 weeks of age
average change in mid arm circumference between baseline and 12 weeks
baseline to average 12 weeks of age
Length
Time Frame: baseline to average 12 weeks of age
average change in length between baseline and 12 weeks
baseline to average 12 weeks of age
Head circumference
Time Frame: baseline to average 12 weeks of age
average change in head circumference between baseline and 12 weeks
baseline to average 12 weeks of age
Caloric intake
Time Frame: 36 weeks
Average difference in weekly caloric intake between groups
36 weeks
Length of stay
Time Frame: 36 weeks or discharge
Days from study entry to discharge home
36 weeks or discharge
Rates of infants less than 10th percentile for weight
Time Frame: 36 weeks or discharge
Rates of infants less than 10th percentile for weight at study completion
36 weeks or discharge
Change in weight z score
Time Frame: 36 weeks or discharge
Change in weight z score from study entry to completion
36 weeks or discharge
Change in length z score
Time Frame: 36 weeks or discharge
Change in length z score from study entry to completion
36 weeks or discharge
Change in head circumference z score
Time Frame: 36 weeks or discharge
Change in head circumference z score from study entry to completion
36 weeks or discharge

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body fat composition
Time Frame: 36 weeks or discharge
Percentage of body fat composition
36 weeks or discharge
Rates of necrotizing enterocolitis (Bell Stage ≥ 2)
Time Frame: 36 weeks or discharge
Safety outcome: Rates of necrotizing enterocolitis (Bell Stage ≥ 2)
36 weeks or discharge
Rates of feeding intolerance
Time Frame: 36 weeks or discharge
Safety outcome: Rates of feeding intolerance defined as withholding feeds for > 24 hours due to gastrointestinal cause after study entry
36 weeks or discharge
Rates of culture proven sepsis
Time Frame: 36 weeks or discharge
Safety outcome: Rates of blood culture positive sepsis after study entry
36 weeks or discharge
Duration of respiratory support
Time Frame: 36 weeks or discharge
Safety outcome: Duration of respiratory support (oxygen, continuous positive airway pressure/high flow nasal cannula/mechanical ventilation) after study entry
36 weeks or discharge
Rates of bronchopulmonary dysplasia
Time Frame: 36 weeks or discharge
Safety outcome: Rates of bronchopulmonary dysplasia
36 weeks or discharge
Rates of moderate to large or symptomatic patent ductus arteriosus
Time Frame: 36 weeks or discharge
Safety outcome: Rates of moderate to large or symptomatic patent ductus arteriosus after study entry
36 weeks or discharge
Rates of adverse safety outcomes combined
Time Frame: 36 weeks or discharge
Safety outcome: Safety outcome: Rates of bronchopulmonary dysplasia, necrotizing enterocolitis ≥ stage 2, feeding intolerance, culture proven sepsis, patent ductus arteriosus after study entry
36 weeks or discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Colm Travers, MD, University of Alabama at Birmingham
  • Ariel A Salas, MD, University of Alabama at Birmingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

June 1, 2018

Study Completion (Actual)

June 1, 2018

Study Registration Dates

First Submitted

December 1, 2014

First Submitted That Met QC Criteria

February 24, 2015

First Posted (Estimate)

March 3, 2015

Study Record Updates

Last Update Posted (Actual)

June 18, 2018

Last Update Submitted That Met QC Criteria

June 14, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • UAB NEO 013

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infant Premature

Clinical Trials on Higher Volume Feeding Goal

3
Subscribe